BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 23148692)

  • 1. Histone demethylase GASC1--a potential prognostic and predictive marker in invasive breast cancer.
    Berdel B; Nieminen K; Soini Y; Tengström M; Malinen M; Kosma VM; Palvimo JJ; Mannermaa A
    BMC Cancer; 2012 Nov; 12():516. PubMed ID: 23148692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Keratin 17 is overexpressed and predicts poor survival in estrogen receptor-negative/human epidermal growth factor receptor-2-negative breast cancer.
    Merkin RD; Vanner EA; Romeiser JL; Shroyer ALW; Escobar-Hoyos LF; Li J; Powers RS; Burke S; Shroyer KR
    Hum Pathol; 2017 Apr; 62():23-32. PubMed ID: 27816721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High levels of γ-glutamyl hydrolase (GGH) are associated with poor prognosis and unfavorable clinical outcomes in invasive breast cancer.
    Shubbar E; Helou K; Kovács A; Nemes S; Hajizadeh S; Enerbäck C; Einbeigi Z
    BMC Cancer; 2013 Feb; 13():47. PubMed ID: 23374458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lectin histochemistry reveals SNA as a prognostic carbohydrate-dependent probe for invasive ductal carcinoma of the breast: a clinicopathological and immunohistochemical auxiliary tool.
    dos-Santos PB; Zanetti JS; Vieira-de-Mello GS; Rêgo MB; Ribeiro-Silva A A; Beltrão EI
    Int J Clin Exp Pathol; 2014; 7(5):2337-49. PubMed ID: 24966944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship Between Histone Deacetylase 3 (HDAC3) and Breast Cancer.
    Cui Z; Xie M; Wu Z; Shi Y
    Med Sci Monit; 2018 Apr; 24():2456-2464. PubMed ID: 29680858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes.
    Habibi G; Leung S; Law JH; Gelmon K; Masoudi H; Turbin D; Pollak M; Nielsen TO; Huntsman D; Dunn SE
    Breast Cancer Res; 2008; 10(5):R86. PubMed ID: 18925950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomic amplification and oncogenic properties of the GASC1 histone demethylase gene in breast cancer.
    Liu G; Bollig-Fischer A; Kreike B; van de Vijver MJ; Abrams J; Ethier SP; Yang ZQ
    Oncogene; 2009 Dec; 28(50):4491-500. PubMed ID: 19784073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IMP3 is a novel biomarker for triple negative invasive mammary carcinoma associated with a more aggressive phenotype.
    Walter O; Prasad M; Lu S; Quinlan RM; Edmiston KL; Khan A
    Hum Pathol; 2009 Nov; 40(11):1528-33. PubMed ID: 19695680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histone demethylase GASC1, a potential prognostic and predictive marker in esophageal squamous cell carcinoma.
    Sun LL; Holowatyj A; Xu XE; Wu JY; Wu ZY; Shen JH; Wang SH; Li EM; Yang ZQ; Xu LY
    Am J Cancer Res; 2013; 3(5):509-17. PubMed ID: 24224128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclooxygenase-2 (COX2) and p53 protein expression are interdependent in breast cancer but not associated with clinico-pathological surrogate subtypes, tumor aggressiveness and patient survival.
    Serra KP; Peres RM; Sarian LO; Vassallo J; Pinto GA; Silva GR; Soares FA; da Cunha IW; Espinola J; Bento AM; Del Corso LM; Derchain S
    Acta Histochem; 2016 Mar; 118(2):176-82. PubMed ID: 26791786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
    Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of molecular classification of breast invasive ductal carcinoma.
    Muñoz M; Fernández-Aceñero MJ; Martín S; Schneider J
    Arch Gynecol Obstet; 2009 Jul; 280(1):43-8. PubMed ID: 19082617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicopathological characteristics of oestrogen receptor negative, progesterone receptor positive breast cancers: re-evaluating subsets within this group.
    Ahmed SS; Thike AA; Zhang K; Lim JC; Tan PH
    J Clin Pathol; 2017 Apr; 70(4):320-326. PubMed ID: 27612503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Negative/low HER2 expression alone or combined with E-cadherin positivity is predictive of better prognosis in patients with breast carcinoma.
    Karray-Chouayekh S; Trifa F; Khabir A; Sellami-Boudawara T; Frikha M; Gargouri A; Mokdad-Gargouri R
    Histol Histopathol; 2012 Mar; 27(3):377-85. PubMed ID: 22237715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High fibroblast growth factor 19 (FGF19) expression predicts worse prognosis in invasive ductal carcinoma of breast.
    Buhmeida A; Dallol A; Merdad A; Al-Maghrabi J; Gari MA; Abu-Elmagd MM; Chaudhary AG; Abuzenadah AM; Nedjadi T; Ermiah E; Al-Thubaity F; Al-Qahtani MH
    Tumour Biol; 2014 Mar; 35(3):2817-24. PubMed ID: 24248542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prognostic role of HER2 expression in ductal breast carcinoma in situ (DCIS); a population-based cohort study.
    Borgquist S; Zhou W; Jirström K; Amini RM; Sollie T; Sørlie T; Blomqvist C; Butt S; Wärnberg F
    BMC Cancer; 2015 Jun; 15():468. PubMed ID: 26062614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation between epidermal growth factor receptor and tumor stem cell markers CD44/CD24 and their relationship with prognosis in breast invasive ductal carcinoma.
    Zheng Z; Shao N; Weng H; Li W; Zhang J; Zhang L; Yang L; Ye S
    Med Oncol; 2015 Jan; 32(1):275. PubMed ID: 25429827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term survival of women with basal-like ductal carcinoma in situ of the breast: a population-based cohort study.
    Zhou W; Jirström K; Johansson C; Amini RM; Blomqvist C; Agbaje O; Wärnberg F
    BMC Cancer; 2010 Nov; 10():653. PubMed ID: 21118480
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Groheux D; Martineau A; Teixeira L; Espié M; de Cremoux P; Bertheau P; Merlet P; Lemarignier C
    Breast Cancer Res; 2017 Jan; 19(1):3. PubMed ID: 28057031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive value of CD44 and CD24 for prognosis and chemotherapy response in invasive breast ductal carcinoma.
    Chen Y; Song J; Jiang Y; Yu C; Ma Z
    Int J Clin Exp Pathol; 2015; 8(9):11287-95. PubMed ID: 26617852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.